Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ro 24-7429 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Ro 24-7429 | DRUG | - |
Inclusion Criteria Patients must have: * HIV seropositivity. * Biopsy-proven mucocutaneous Kaposi's sarcoma with fewer than 50 skin lesions and measurable disease. * No active opportunistic infection. NOTE: * Patients with CD4 count \>= 200 cells/mm3 must have no prior opportunistic infection, as ...
Ro 24-7429 is an investigational small molecule being studied for the treatment of Kaposi's sarcoma, a type of cancer often associated with HIV infection. It is being developed by Roche Holding AG (ticker: RHHBY) and has completed a Phase 2 clinical trial in patients with HIV-related Kaposi's sarcoma.
Ro 24-7429 is being developed by Roche Holding AG, a multinational healthcare company traded under the ticker RHHBY. The drug is an investigational small molecule in the oncology therapeutic area, and it has been studied in a Phase 2 clinical trial for Kaposi's sarcoma.
Ro 24-7429 is in Phase 2 clinical development. It has completed one Phase 2 trial, and there are no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities for any use.
Ro 24-7429 has been studied in one completed clinical trial, identified as NCT00002314. This Phase 2 study, titled 'A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma,' was conducted in the United States and enrolled adult patients with Kaposi's sarcoma and HIV infections.
Ro 24-7429 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is a small molecule being developed by Roche Holding AG for Kaposi's sarcoma.